Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Among authors: grosicki s. Eur J Haematol. 2003 Sep;71(3):155-62. doi: 10.1034/j.1600-0609.2003.00122.x. Eur J Haematol. 2003. PMID: 12930315 Clinical Trial.
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study.
Jagannath S, Delimpasi S, Grosicki S, Van Domelen DR, Bentur OS, Špička I, Dimopoulos MA. Jagannath S, et al. Among authors: grosicki s. Clin Lymphoma Myeloma Leuk. 2023 Dec;23(12):917-923.e3. doi: 10.1016/j.clml.2023.08.018. Epub 2023 Aug 29. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37743180 Free article. Clinical Trial.
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Bringhen S, Pour L, Benjamin R, Grosicki S, Min CK, C de Farias DL, Vorog A, Labotka RJ, Wang B, Cherepanov D, Cain LE, Manne S, Rajkumar SV, Dimopoulos MA. Bringhen S, et al. Among authors: grosicki s. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):491-504. doi: 10.1016/j.clml.2023.03.007. Epub 2023 Mar 29. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37149398 Free article. Clinical Trial.
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Walewski J, Kraszewska E, Mioduszewska O, Romejko-Jarosińska J, Hellmann A, Czyz J, Hołowiecki J, Kopera M, Grosicki S, Komarnicki M, Rumianowski L, Kuliczkowski K, Wróbel T, Dwilewicz-Trojaczek J, Robak T, Warzocha K, Załuski J, Wójcik E, Dmoszyńska A, Walter-Croneck A; Polish Lymphoma Research Group. Walewski J, et al. Among authors: grosicki s. Med Oncol. 2001;18(2):141-8. doi: 10.1385/mo:18:2:141. Med Oncol. 2001. PMID: 11778760 Clinical Trial.
G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study.
Hołowiecki J, Giebel S, Krzemień S, Krawczyk-Kuliś M, Jagoda K, Kopera M, Hołowiecka B, Grosicki S, Hellmann A, Dmoszyńska A, Paluszewska M, Robak T, Konopka L, Maj S, Wojnar J, Wojciechowska M, Skotnicki A, Baran W, Cioch M. Hołowiecki J, et al. Among authors: grosicki s. Leuk Lymphoma. 2002 Feb;43(2):315-25. doi: 10.1080/10428190290006099. Leuk Lymphoma. 2002. PMID: 11999563 Clinical Trial.
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Holowiecki J, et al. Among authors: grosicki s. Leukemia. 2004 May;18(5):989-97. doi: 10.1038/sj.leu.2403336. Leukemia. 2004. PMID: 14999298 Clinical Trial.
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Among authors: grosicki s. Ann Hematol. 2005 Sep;84(9):557-64. doi: 10.1007/s00277-005-1046-0. Epub 2005 Apr 27. Ann Hematol. 2005. PMID: 15856358 Clinical Trial.
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.
Holowiecki J, Grosicki S, Sadus-Wojciechowska M, Kachel L, Hellmann A, Mital A, Skotnicki AB, Piatkowska-Jakubas B, Jedrzejczak WW, Paluszewska M, Wach M, Marianska B, Wrzesien-Kus A, Krawczyk-Kulis M, Wojnar J. Holowiecki J, et al. Among authors: grosicki s. Transplant Proc. 2005 Dec;37(10):4482-7. doi: 10.1016/j.transproceed.2005.10.100. Transplant Proc. 2005. PMID: 16387150
The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, Reiter A, Hochhaus A, Holowiecki J. Helbig G, et al. Among authors: grosicki s. Eur J Haematol. 2006 Jun;76(6):535-6. doi: 10.1111/j.1600-0609.2006.00652.x. Epub 2006 Apr 11. Eur J Haematol. 2006. PMID: 16608506 No abstract available.
143 results